CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Phase 2 ...

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe's Atomico and Silicon Valley-based R42.

Healx, a leading AI-driven drug discovery company focused on rare diseases, announces Christopher Moertel, M.D., as Global Head of Clinical Development We are thrilled to welcome Dr. Moertel to ...

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...

Healx, an artificial intelligence (AI)-based drug developer focused on treating rare diseases, said it dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe's Atomico and Silicon Valley-based R42. The company also ...